|Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-track revascularization in unstable coronary artery disease.|
|PMID: 11251354 Owner: NLM Status: MEDLINE|
|Revascularization procedures and particularly percutaneous transluminal coronary angioplasty are being performed more and more often in patients with unstable coronary artery disease, despite the fact that these procedures are known to carry a higher risk in such patients than in those with stable disease. This article reviews studies that have investigated the potential of modern antithrombotic therapy -- low-molecular-weight heparin, anti-Xa agents, direct antithrombin inhibitors and glycoprotein IIb/IIIa inhibitors -- to reduce the post-procedural event rate in such patients. The results are promising.|
|J P Bassand|
Related Documents :
|8730644 - Is aspirin, as used for antithrombosis, an emotion-modulating agent?
8950124 - Ancrod: the use of snake venom in the treatment of patients with heparin-induced thromb...
14551514 - The management of unstable angina and non-st-segment elevation myocardial infartion.
16816444 - Desensitization for the management of clopidogrel hypersensitivity: initial clinical ex...
9873904 - Motion and deformation tracking for short-axis echo-planar myocardial perfusion imaging.
10716134 - Left ventricular function and autonomic nervous system balance during two different sta...
|Type: Journal Article; Review|
|Title: Haemostasis Volume: 30 Suppl 2 ISSN: 0301-0147 ISO Abbreviation: Haemostasis Publication Date: 2000|
|Created Date: 2001-03-19 Completed Date: 2001-07-05 Revised Date: 2013-05-24|
Medline Journal Info:
|Nlm Unique ID: 0371574 Medline TA: Haemostasis Country: Switzerland|
|Languages: eng Pagination: 114-21; discussion 106-7 Citation Subset: IM|
|Copyright 2001 S. Karger AG, Basel|
|Department of Cardiology, University Hospital Jean-Minjoz, Besançon, France. email@example.com|
|APA/MLA Format Download EndNote Download BibTex|
Angioplasty, Balloon, Coronary
Antibodies, Monoclonal / therapeutic use
Anticoagulants / administration & dosage, therapeutic use*
Aspirin / administration & dosage, therapeutic use
Clinical Trials as Topic
Combined Modality Therapy
Drug Therapy, Combination
Factor Xa / antagonists & inhibitors
Heparin, Low-Molecular-Weight / administration & dosage, therapeutic use*
Hirudins / administration & dosage, analogs & derivatives
Immunoglobulin Fab Fragments / therapeutic use
Oligosaccharides / administration & dosage, therapeutic use
Peptide Fragments / administration & dosage, therapeutic use
Peptides / therapeutic use
Platelet Aggregation Inhibitors / administration & dosage, therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
Postoperative Complications / prevention & control
Randomized Controlled Trials as Topic
Recombinant Proteins / administration & dosage, therapeutic use
Thrombocytopenia / chemically induced
Thrombosis / prevention & control*
Tyrosine / analogs & derivatives*, therapeutic use
|0/Antibodies, Monoclonal; 0/Anticoagulants; 0/Heparin, Low-Molecular-Weight; 0/Hirudins; 0/Immunoglobulin Fab Fragments; 0/Oligosaccharides; 0/PENTA; 0/Peptide Fragments; 0/Peptides; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/Recombinant Proteins; 0/eptifibatide; 128270-60-0/bivalirudin; 144494-65-5/tirofiban; 50-78-2/Aspirin; 55520-40-6/Tyrosine; EC 188.8.131.52/Factor Xa; X85G7936GV/abciximab|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery dis...
Next Document: Low-molecular-weight heparin and other antithrombotic agents in the setting of a primarily medical t...